Phase I/II study of HSP90 inhibitor AUY922 and Erlotinib for EGFR-Mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors

Journal of Clinical Oncology

Volumn 33, Issue 15, 2015, Pages 1666-1673

  Johnson, Melissa L ^a   Yu, Helena A ^b   Hart, Eric M ^a   Weitner, Bing Bing ^a   Rademaker, Alfred W ^a   Patel, Jyoti D ^a   Kris, Mark G ^b   Riely, Gregory J ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GLUCOSE; LOPERAMIDE; LUMINESPIB; METHIONINE; THREONINE; 5-(2,4-DIHYDROXY-5-ISOPROPYLPHENYL)-4-(4-MORPHOLIN-4-YLMETHYLPHENYL)ISOXAZOLE-3-CARBOXYLIC ACID ETHYLAMIDE; ANTINEOPLASTIC AGENT; CHAPERONE; HEAT SHOCK PROTEIN 90; ISOXAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; RESORCINOL DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL EVALUATION; COLITIS; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FATIGUE; FEMALE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MIDDLE AGED; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; NIGHT BLINDNESS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; VISUAL DISORDER; ANTAGONISTS AND INHIBITORS; BIOPSY; CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG RESISTANCE; LUNG NEOPLASMS; METABOLISM; MUTATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOLECULAR CHAPERONES; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESORCINOLS; TREATMENT OUTCOME;

EID: 84933509294     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.7328     Document Type: Article

References (41)

1. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
2. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500, 2004
3. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
4. Yang JC, Shih JY, Su WC, et al: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol 13:539-548, 2012
5. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
6. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334, 2013
7. Rosell R, Carcereny E, Garvais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
8. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
9. Balak MN, Gong Y, Riely GJ, et al: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494-6501, 2006
10. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-20937, 2007
11. Engelman JA, Zejnullanu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007
12. Takezawa K, Pirazzoli V, Arcila ME: HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2:922-933, 2012
13. Zhang Z, Lee JC, Lin L, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852-860, 2012
14. Yu HA, Arcila ME, Rekhtman N, et al: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19:2240-2247, 2013
15. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26, 2011
16. Ohashi K, Sequist LV, Arcila ME, et al: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109:E2127-E2133, 2012
17. Janne PA, Ramalingam SS, Yang JCH, et al: Clinical activity of the mutant selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 32:508s, 2014 (suppl 15s; abstr 8009)
18. Sequist LV, Soria JC, Gadgeel SM, et al: First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 32:508s, 2014 (suppl 15s; abstr 8010)
19. Kim DW, Lee DH, Kang JH, et al: Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs). J Clin Oncol 32:508s, 2014 (suppl 15s; abstract 8011)
20. Neckers L, Workman P: Hsp90 molecular chaperone inhibitors: Are we there yet? Clin Cancer Res 18:64-76, 2012
21. Shimamura T, Lowell AM, Engelman JA, et al: Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destablized following exposure to geldanamycins. Cancer Res 65:6401-6408, 2005
22. Sessa C, Shapiro GI, Bhalla KN, et al: First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 19:3671-3680, 2013
23. Ueno T, Tsukuda k, Toyooka S, et al: Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer 76:26-31, 2012
24. Garon EB, Finn RS, Habib H, et al: The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther 12:890-900, 2013
25. Garon EB, Moran T, Barlesi F, et al: Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). J Clin Oncol 30:490s, 2012 (suppl; abstr 7543)
26. th World Conference on Lung Cancer, Sydney, Australia, October 27-31, 2013 (abstr 2730)
27. Chmielecki J, Foo J, Oxnard GR, et al: Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3:90ra59, 2011
28. Riely GJ, Kris MG, Zhao B, et al: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150-5155, 2007
29. Chaft JE, Oxnard GR, Sima CS, et al: Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design. Clin Cancer Res 17:6298-6303, 2011
30. Jackman D, Pao W, Riely GJ, et al: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28:357-360, 2010
31. Sequist LV, Gettinger S, Senzer NN, et al: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28:4953-4960, 2010
32. Socinski MA, Goldman J, El-Hariry I, et al: A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19:3068-3077, 2013
33. Wu WC, Wu MH, Chang YC, et al: Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells. Exp Eye Res 91:211-219, 2010
34. Zhou D, Yuan L, Ye J, et al: A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats. Mol Cancer Ther 10, 2011 (suppl; abstr C212)
35. Goldman JW, Raju RN, Gordon GA, et al: A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 13:152, 2013
36. Munk MR, Fernandes J, Mets M, et al: Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-HSP90 therapy. JAMA Ophthalmol 132:899-901, 2014
37. Mitsudomi T, Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277:301-308, 2010
38. Janjigian YY, Smit EF, Groen HJ, et al: Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 4:1036-1045, 2014
39. Riely GJ, Pao W, Pham D, et al: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839-844, 2006
40. Kato T, Seto T, Nishio M, et al: Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as firstline treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. J Clin Oncol 32:507s, 2014 (suppl 15s; abstr 8005)
41. Yang, JCH, Sequist, LV, Schuler MH, et al: Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). J Clin Oncol 32:507s, 2014 (suppl 15s; abstr 8004)